Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RC48-ADC in mCRPC After Novel Endocrine Therapy
NCT05955209Phase 2Unknown
- Sponsor
- Peking University Cancer Hospital & Institute
- Start
- Aug 2023
- Primary completion
- Aug 2024
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
01
Overview
A Phase 2 trial of disitamab vedotin in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Peking University Cancer Hospital & Institute. Status: unknown.
02
Drugs
disitamab vedotin
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT05955209.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05955209.